|Day Low/High||9.45 / 9.96|
|52 Wk Low/High||4.30 / 12.60|
Investors in Arbutus Biopharma Corp saw new options become available this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABUS options chain for the new August 17th contracts and identified one put and one call contract of particular interest.
Detailed Data to be Presented at AASLD in October
In recent trading, shares of Arbutus Biopharma Corp have crossed above the average analyst 12-month target price of $6.62, changing hands for $6.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
An Examination of the Rapidly Emerging field of mRNA Therapeutics in a Live Webinar hosted by the Nucleic Acid Drug Delivery Leader Arbutus Biopharma
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.